Patents Assigned to Takeda
  • Heterocyclic compound
    Patent number: 9371320
    Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: June 21, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Hiroshi Nara, Masaki Daini, Akira Kaieda, Toshihiro Imaeda, Fumiaki Kikuchi
  • COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT
    Publication number: 20160166526
    Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 16, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: NAOMI KITAMOTO
  • Heterocyclic compound
    Patent number: 9365520
    Abstract: The present invention provides a heterocyclic compound having a ROR?t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification. or a salt thereof.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: June 14, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoshi Yamamoto, Junya Shirai, Tsuneo Oda, Mitsunori Kono, Atsuko Ochida, Takashi Imada, Hidekazu Tokuhara, Yoshihide Tomata, Naoki Ishii, Michiko Tawada, Yoshiyuki Fukase, Tomoya Yukawa, Shoji Fukumoto
  • Process for producing solid particles
    Patent number: 9364438
    Abstract: A method of producing crystal of a poorly water-soluble pharmaceutical compound, including mixing a solution of a poorly water-soluble pharmaceutical compound in a good solvent and nanobubble water or an aqueous nanobubble solution to precipitate crystal of the poorly water-soluble pharmaceutical compound. The crystal of a poorly water-soluble pharmaceutical compound obtained by the method is microparticulate and has more uniform particle size distribution, and is superior in the absorbability and sustainability.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: June 14, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Naoyuki Murata, Shigeo Yanai
  • Cinnoline derivatives
    Patent number: 9365566
    Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: June 14, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: John David Lawson, Mark Sabat, Christopher Smith, Haixia Wang, Young K. Chen, Toufike Kanouni
  • Benzimidazole derivatives as MCH receptor antagonists
    Patent number: 9365540
    Abstract: The present invention provides an aromatic ring compound having a melanin-concentrating hormone receptor antagonistic action and useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula wherein each symbol as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: June 14, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shizuo Kasai, Hideyuki Igawa, Masashi Takahashi, Tsuyoshi Maekawa, Keiko Kakegawa, Asato Kina, Jumpei Aida, Uttam Khamrai, Mrinalkanti Kundu
  • HETEROCYCLIC COMPOUND
    Publication number: 20160159773
    Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 9, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Morihisa Saitoh, Takatoshi Yogo, Taku Kamei, Norihito Tokunaga, Yusuke Ohba, Takafumi Yukawa
  • Virus like particle purification
    Patent number: 9359410
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: June 7, 2016
    Assignee: TAKEDA VACCINES INC.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Tetrahydronaphthyridine somatostatin receptor 5 antagonists
    Patent number: 9353108
    Abstract: A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 31, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Hideki Hirose, Takeshi Yamasaki, Tohru Yamashita, Asato Kina
  • 5-HT3 receptor antagonists
    Patent number: 9346829
    Abstract: The present invention provides a method of treating nicotine addiction comprising administering a 5-HT3 receptor antagonists of Formula (I):
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: May 24, 2016
    Assignee: Takeda Phamaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • Fused heterocyclic compound
    Patent number: 9346776
    Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: May 24, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Zenichi Ikeda, Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Yoichi Nishikawa
  • Thienopyrimidine compounds and use thereof
    Patent number: 9346822
    Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: May 24, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
  • 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD
    Patent number: 9345713
    Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: May 24, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Method and apparatus for producing oxidized compound
    Patent number: 9346783
    Abstract: A method of producing an oxidized compound is disclosed. An electric potential is measured of an oxidation reaction solution for producing an oxidized compound by an oxidation reaction, and an end point is determined of the oxidation reaction on the basis of a predefined decrease of the electric potential. Preferably, after the electric potential of the oxidation reaction solution is reached to a highest electric potential, a point is determined where the amount of an electric potential dropped from the highest electric potential reaches the predefined amount of an electric potential as the end point of the oxidation reaction. The method also may introduce an oxidation reaction terminating agent to the oxidation reaction solution immediately after determining the end point of the oxidation reaction.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 24, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masayoshi Kaneko, Shigeo Yabuno, Kenji Iwaoka, Hidetoshi Nishimura
  • Pyrazolone-derivatives and their use as PDE-4 inhibitors
    Patent number: 9340522
    Abstract: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: May 17, 2016
    Assignee: TAKEDA GMBH
    Inventors: Imre Schlemminger, Beate Schmidt, Dieter Flockerzi, Hermann Tenor, Christof Zitt, Armin Hatzelmann, Degenhard Marx, Clemens Braun, Raimund Kuelzer, Anke Heuser, Hans-Peter Kley, Geert Jan Sterk
  • Laminated tablet and manufacturing method therefor
    Patent number: 9326946
    Abstract: According to the present invention, a multilayer tablet showing suppressed layer separation and a production method thereof are provided. A concave portion having a depth of not less than 0.1 mm Ka is formed on at least one surface Sa of the both front and back surfaces (Sa, Sb) of a multilayer tablet. Particularly, a multilayer structure obtained by, in tableting, forming a convex portion for forming the concave portion on at least the upper punch, and preliminarily compressing all layers in the multilayer tablet with the upper punch to form a concave portion having the same shape with a depth of not less than 0.1 mm on the upper surface of all layers, wherein the powder materials of the next layer are protruding into the concave portion, is a preferable embodiment.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: May 3, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kazuki Harada, Hikaru Fukuyama, Masahiko Koike
  • AROMATIC COMPOUND
    Publication number: 20160115128
    Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.
    Type: Application
    Filed: August 8, 2014
    Publication date: April 28, 2016
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jumpei AIDA, Yayoi YOSHITOMI, Yuko HITOMI, Naoyoshi NOGUCHI, Yasuhiro HIRATA, Hideki FURUKAWA, Akito SHIBUYA, Koji WATANABE, Yasufumi MIYAMOTO, Tomohiro OKAWA, Nobuyuki TAKAKURA, Seiji MIWATASHI
  • CONTROLLED-RELEASE DRUG FORMULATION
    Publication number: 20160113913
    Abstract: The present invention provides a controlled-release solid preparation containing pioglitazone or a salt thereof as an active ingredient, and having superior sustainability. A controlled-release solid preparation containing pioglitazone or a salt thereof as an active ingredient, which is composed of an immediate-release part and a sustained-release part in combination.
    Type: Application
    Filed: April 18, 2014
    Publication date: April 28, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yusuke Murakawa, Shunichiro Tsutsumi, Kaoru Takenaka, Kanako Inoo
  • Tablet
    Patent number: 9320714
    Abstract: The present invention can retain the volume of a tablet large without increasing the thickness of the tablet or the like dimension and prevents a plurality of tablets from sticking to each other even if they are subjected to a film-coating or the like treatment, so as to improve the yield. The tablet is a tablet (1) longer in one direction when seen in plan. The tablet (1) has side edges (6) each of which extends in a longitudinal direction and is formed in the shape of a curve projecting outwardly in plan view. The curve has a radius of curvature (R1) set to at least 1.5 times a length (L) of the tablet. This makes a projected area of the tablet (1) in plan view at least 97% with respect to a projected area of a standard elliptical tablet having opposite end portions each of which is formed by a semi-circle having a diameter of a width (W) of the tablet.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: April 26, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Masahiko Koike, Hiroyoshi Koyama
  • Heterocyclic compound
    Patent number: 9321757
    Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: April 26, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masato Yoshida, Kazuaki Takami, Yusuke Tominari, Zenyu Shiokawa, Akito Shibuya, Yusuke Sasaki, Tony Gibson, Terufumi Takagi